SG1408 is an innovative bi-specific antibody therapeutic biological candidate developed by CNBG-Sumgen. It has received IND clearance from NMPA and a Ph I clinical trial for the treatment of late stage solid tumor is ongoing in China.
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044
